In the ApoE–/– mouse model, results showed sensitive and specific detection of CCR5 in plaques not only along the progression of atherosclerotic lesions, but also during plaque regression and the human ex vivo experiment, which confirmed the potential of CCR5 targeting in human atherosclerosis [73]. The gene discussed is APOE; the disease is atherosclerosis.